{'fraction_non_alphanumeric': 0.04, 'fraction_numerical': 0.02553191489361702, 'mean_word_length': 5.391304347826087, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of Histamine Release Following Intravenous Injection of Ionic and Nonionic Contrast Media

Pinet A, Corot C, Biot N, Eloy R. Evaluation of histamine release following intravenous injection of ionic and nonionic contrast media. Invest Radiol 1988;23(Suppl 1):S174‐S177. To evaluate histamine release (HR) following injection of radiocontrast media and to test the predictive value of peak‐expiratoryflow rate (PEFR) in detecting high‐risk patients, the authors performed in two series 90 intravenous pyelograms (IVPs). In the first group, HR was measured by a fluorometric method after injection of Hexabrix (25 patients) and Iopamiron (25 patients). In the second group, HR measured by a radioimmunoassay, and PEFR measured by a peak flowmeter were investigated after injection of Hexabrix (10 patients), Telebrix (10 patients), Omnipaque (10 patients) and Iopamiron (10 patients). Histamine release in groups 1 and 2, and PEFR in group 2, were not significantly modified by the injection of each radiocontrast media. For the four patients (two per group) who experienced minor allergic side effects, the levels of HR and PEFR were always within the normal ranges.